טוען...
Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans
BACKGROUND: Efavirenz is commonly used in Africa and is frequently associated with neurocognitive toxicity, which may compromise clinical outcomes. Older individuals are at increased risk for drug toxicity and clinical outcomes may be worse in older age, particularly among those individuals with cyt...
שמור ב:
| הוצא לאור ב: | Eur J Drug Metab Pharmacokinet |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6420397/ https://ncbi.nlm.nih.gov/pubmed/30168000 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13318-018-0507-5 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|